PATENT CLAIM ANALYSIS

Application Number: 16054539
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["424", "204100"]

Abstract:
Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.

Claim (Index 42):
The method of  claim 41 , wherein the HEV VLP or a component thereof enters the cancer cell.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.67123
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15312582', '13220356', '14533531', '13224151', '15082401']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7555876485659109
- 35 USC 102 Novelty (BERT): 0.626518945214742
- Combined Prediction Score: 0.742680778230794
- Mean Citation Score: 469.887096
- Max Citation Score: 827.0026
- Similarity Product: 494.84946734547617

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test